Table 3.
Biosimilars of bevacizumab
| Name of Biosimilar | Manufacturer | Approval Stage |
|---|---|---|
| Zirabev | Pfizer (USA) | US FDA (2019), EMA (2019) |
| ABP215 (Mvasi) | Amgen (Thousand Oaks, CA, USA) and Allergan (Dublin, Ireland) | US FDA (2017), EMA (2017) |
| Cizumab | Hetero (Hyderabad, India) | DGCI (2016) |
| Bevacirel | Reliance Life Sciences (Mumbai, India) | DGCI (2016) |
| BCD-021 | Biocad (Saint Petersburg, Russia) | Russian Regulatory Body (2015) |
| mAbxience | mAbxience (Madrid, Spain) | Argentina Regulatory Body (2016) |
| Krabeva | Biocon (Bangalore, India) | DGCI (2017) |
| Zybev | Zydus Cadila (Ahmedabad, India) | DGCI (2017) |
| Abevmy | Mylan Pharmaceuticals (South Africa) | DGC! (2017) |
| Bevatas | Intas (Ahmedabad, India) | DGCI (2017) |